BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)
China flag China · Delayed Price · Currency is CNY
32.94
+1.11 (3.49%)
At close: Jul 31, 2026

SHA:688166 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
1,395961.06765.35998.051,180336.84
Trading Asset Securities
---50.6250.120.76
Cash & Short-Term Investments
1,395961.06765.351,0491,230337.6
Cash Growth
71.70%25.57%-27.02%-14.78%264.48%-35.02%
Accounts Receivable
388.73330.02339.5308.88307.47373.85
Other Receivables
3.289.136.6619.9118.783.75
Receivables
392.01339.14346.17328.79326.25377.59
Inventory
358.51364.25364.61344.63280.35200.06
Prepaid Expenses
---3.655.834.48
Other Current Assets
160.77124.04164.1411495.3973.27
Total Current Assets
2,3071,7891,6401,8401,938993.01
Property, Plant & Equipment
2,8022,7522,7052,4892,0761,378
Long-Term Investments
476.18671.08437.06425.86399.33348.28
Goodwill
--3.127.57.57.5
Other Intangible Assets
78.3979.5389.4893.6681.6480.84
Long-Term Accounts Receivable
-4.12.1---
Long-Term Deferred Tax Assets
111.3594.6862.242.2823.9419.86
Long-Term Deferred Charges
354.98339.1957.4930.1826.8725.83
Other Long-Term Assets
405.3595.42156.03104.09107.73115.86
Total Assets
6,5355,8255,1535,0324,6612,970

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
144.17185.89266228.18252.19211.89
Accrued Expenses
38.3282.9772.0172.3169.0461.72
Short-Term Debt
68.93110.11115.26156.87124.38257.05
Current Portion of Long-Term Debt
659.29775.1516.96397.93313.8716.58
Current Portion of Leases
-8.8313.6916.11.349.87
Current Income Taxes Payable
17.5810.6116.6814.0414.973.69
Current Unearned Revenue
31.7325.5628.022429.4920.33
Other Current Liabilities
31.2581.2323.7612.816.261.93
Total Current Liabilities
991.271,2801,052922.25811.52583.07
Long-Term Debt
2,3351,4901,5801,6151,576618.69
Long-Term Leases
2610.2110.2121.016.010.22
Long-Term Unearned Revenue
155.27167.5884.7126.252626
Other Long-Term Liabilities
126.1430.3-29.82--
Total Liabilities
3,6332,9792,7272,6142,4201,228

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
423.1423.1422.47422.47422.47410
Additional Paid-In Capital
1,0761,076982.361,0571,008738.94
Retained Earnings
1,0761,0661,046897.66743.35555.05
Treasury Stock
-20.05-20.05-10.01---
Comprehensive Income & Other
-24.54-24.21-57.82-8.6417.77-25.8
Total Common Equity
2,5302,5212,3832,3692,1921,678
Minority Interest
371.26325.0142.7348.9750.0463.45
Shareholders' Equity
2,9022,8462,4262,4182,2421,742
Total Liabilities & Equity
6,5355,8255,1535,0324,6612,970

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
3,0892,3952,2362,2072,022902.42
Net Cash (Debt)
-1,694-1,433-1,470-1,158-791.15-564.82
Net Cash Growth
------
Net Cash Per Share
-3.96-3.42-3.50-2.75-1.91-1.39
Filing Date Shares Outstanding
422.54422.54422.11422.1422.47410
Total Common Shares Outstanding
422.54422.54422.11422.47422.47410
Working Capital
1,315508.2587.89917.491,127409.94
Book Value Per Share
5.995.975.655.615.194.09
Tangible Book Value
2,4522,4422,2912,2672,1031,590
Tangible Book Value Per Share
5.805.785.435.374.983.88
Buildings
-745.28728.65261.26273.4104.72
Machinery
-1,2711,122704.8318.41287.37
Construction In Progress
-1,1871,1671,7361,6661,131